Current Firm
OrbiMed Advisors
Investments
1+ companies
Focus
Biotech, Digital Health
Matthew Rizzo is a General Partner at OrbiMed Advisors, a leading investment firm specializing in the healthcare and life sciences sectors. With a focus on biotech, digital health, and artificial intelligence, Rizzo identifies and supports innovative companies poised to transform healthcare delivery and outcomes. His investment portfolio includes notable ventures such as Carl L. Gordon, demonstrating his expertise in selecting high-impact opportunities within emerging healthcare technologies. At OrbiMed Advisors, Rizzo leverages deep industry knowledge and a robust network to mentor founders and drive value creation across portfolio companies. His strategic vision encompasses both traditional biotechnology innovations and cutting-edge digital health solutions, positioning him at the intersection of healthcare disruption and technological advancement.
Matthew Rizzo is a General Partner, OrbiMed Advisors at OrbiMed Advisors, based in New York, NY.
Matthew's investment focus spans Biotech, Digital Health, AI, primarily investing at the Series A, Series B+ stages. This specialization allows for deep domain knowledge and strong network effects that benefit portfolio companies.
Notable investments include Carl L. Gordon. These investments span Biotech and Digital Health.
Matthew Rizzo is a General Partner, OrbiMed Advisors at OrbiMed Advisors, based in New York, NY. Their investment focus includes Biotech, Digital Health, AI.
Matthew Rizzo focuses on investments in Biotech, Digital Health, AI through OrbiMed Advisors. These focus areas reflect their domain expertise and the types of startups they actively seek to back.
Matthew Rizzo's notable portfolio investments include Carl L. Gordon. These companies span multiple sectors and stages, reflecting a track record of identifying high-potential startups.
Matthew Rizzo is currently at OrbiMed Advisors, headquartered in New York, NY, serving as General Partner, OrbiMed Advisors.